Clinical trial · Interventional
Impact of Time to Re-staging Transurethral Resection on Recurrence and Progression Rates
Impact of Time to Re-staging Transurethral Resection on Recurrence and Progression Rates in Patient With High-risk Non-muscle-invasive Bladder Cancer: A Prospective, Randomized, Controlled Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose To investigate the significance of time to re-staging transurethral resection (re-TUR) on recurrence and progression rates in patient with high-risk non-muscle-invasive bladder cancer. Methods Patients diagnosed with primary high risk non-muscle-invasive bladder cancer were included to the study. The patients were randomly seperated into 3 groups acoording to Re-TUR timing. In group 1,2, and 3, the time interval between initial and re-TUR were 14-28 days, 29-42 days, and 43-56 days respectively. Kaplan -meier plots were used to estimate differences in recurrence free survival (RFS) and progression free survival (PFS) rates. Cox regression analysis was used to assess the effect of time from initial TUR to re-TUR on oncological outcomes. Results A total of 109 patients with high risk non-muscle-invasive bladder cancer were randomly divided into 3 groups. Twenty patients in group 1 (14-28 days), 22 patients in group 2 (29-42 days), and 29 patients in group 3 (43-56 days) completed the study. The mean follow-up was 20 ± 8.9 months. Kaplan-Meier plots showed no differences in RFS and PFS rates between the three groups. Cox regression analysis demonstrated that only tumor number was found to be a prognostic factor on RFS rates. Conclusion Our prospective study demonstrated that time laps from initial TUR to re-TUR did not significantly affect on RFS and PFS rates.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Second transurehral resection of bladder tumour | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- 14-28 days
- description
- In group 1,the time interval between initial and re-TUR was 14-28 days,
- interventionNames
- Procedure: Second transurehral resection of bladder tumour
- type
- ACTIVE_COMPARATOR
- label
- 29-42 days
- description
- In group 2, the time interval between initial and re-TUR was 29-42 days
- interventionNames
- Procedure: Second transurehral resection of bladder tumour
- type
- ACTIVE_COMPARATOR
- label
- 43-56 days
- description
- In group 3, the time interval between initial and re-TUR was 43-56 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 44 Years
- Maximum age
- 86 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a tumor pathology other than transitional cell carcinoma, incomplete resection at initial TUR, who cannot complete 1 year of maintenance BCG treatment, did not attend their regular cystoscopic control or wanted to leave from the study voluntarily and lastly, with a diagnosis of muscle-invasive cancer on re-TUR were excluded. Exclusion Criteria: * Inclusion criteria were having a high grade Ta or T1 transitional cell carcinoma with or without carcinoma in situ (CIS) after a complete initial TUR of bladder carcinoma, and receiving six weekly induction BCG therapy with at least 1 year maintenance.
References
Publications (0)
Data not yet available